Korelasi Hemostasis Dengan Tumor Marker Pada Pasien Kanker Paru bukan Sel Kecil Dengan Kemoterapi

A. A. Ponomaryova et al, 2011 Molecular Genetic Markers in Diagnosis of Lung
Cancer, Institute of Oncology, Siberian Branch, Russian Academy of
Medical Sciences, Tomsk, 634001 Russia, ISSN 0026_8933, Molecular
Biology, 2011, Vol. 45, No. 2, pp. 175–189.
A. Falanga et al, 2013, Coagulation and cancer: biological and clinical aspects, Jurnal
of Thrombosis and Haemostasis,II,Itali, 2013, 223-233.
Andrew, D Blann, et al, 2011, Arterial and Venous Thrombosis in Cancer Patients,
Cardiology Research and Practice, 2ulation and Anticoagulation.
Annie Young et al, 2012, Thrombosis and cancer, Department of Haematology,
University Hospital, Clifford

Bridge Road, Coventry CV2 2DX, UK.

NATURE REVIEWS | Clinical Oncology, Volume 9 | August 2012.
Anthony Letai and David J Kuter, 1999, Cancer, Coagulation and anticoagulation,
Hematology Oncology Departement, Boston, USA.
Berna Komurcuoglu et al, 2011, prognostic value of plasma D-dimer levels in lung
carcinoma, Tumori 97, Turki, 2011, 743-748
Bo Jin et al, 2010, The Value of Tumor Markers in Evaluating Chemotherapy
Response and Prognosis in Chinese Patients with Advanced Non-Small Cell

Lung Cancer, Department of Pulmonary Medicine, Shanghai Chest Hospital,







Universitas Sumatera Utara

Buku ajar Penyakit Dalam FK UI, 2006, Dasar-dasar Hemostasis dan Thrombosis
pada kanker, Jakarta.

Dangfan Yu et al, 2013, Prognostic Value of Tumor Markers, NSE, CA125 and

Operable NSCLC Patients Department of Nuclear Medicine,

Zhejiang Provincial Corps Hospital, Chinese People‟s ArmedPolice Force,
Jiaxing 314000, China Int. J. Mol. Sci.
D. Ferrigno et al, 1994, Serum tumour markers in lung cancer: history, biology and
clinical applications Dept of Nuclear Medicine, S. Croce General Hospital,
Cuneo, Italy. Eur Respir J, 1994, 7, 186–197,
Ebru Unsal et al, 2003, Prognostic pnificance of hemostatic parameters in patients
with lung cancer,ELSEVIER, Turki 2003.
Faruk Tas et al, 2013, Clinical and prognostic pnificance of coagulation assays in
lung cancer, Institute of Oncology, University of Istanbul, Istanbul, Turkey,
Elsevier Ltd., Respiratory Medicine, 2013, 107, 451e457
Gerald A. Soff, 2013, Pathophysiology and management of thrombosis in cancer:150
years of progress, J Thromb Thrombolysis (2013) 35:346–351 DOI
IASLC/ATS/ERS, 2011, Internasional Multidisciplinary Classfisication of Lung
Adenocarcinoma, Journal of Thoracic Oncology, IASLC.

Isabel Dos Santos Silva, 2010, Circulating Levels of Coagulation and Inflammatin
markers and cancer risks: individual participant analysis af data from three
long-terms cohort, Departement of Epidemiology and Population health,
Universitas Sumatera Utara

London school of Hygiene and Tropical Medicine, London, International
Journal of Epidemiology, London.
Jung zao et al, 2012, Tumor response and survival in patients with advanced nonsmall-cell lung cancer: the predictive value of chemotherapy-induced
changes in fibrinogen, Department of Medical Oncology, The First Hospital,
China Medical University, Shenyang, China, Zhao et al. BMC Cancer 2012,
12:330. http://www.biomedcentral.com 1471-2407/12/330
Kementrian Kesehatan Republik Indonesia, 2011, Pedoman Interpretasi Data Klinik,
Kostas D.Hatzakis et al, 2002, Prognostic Value of Serum Tumor Markers in Patients
with Lung Cancer, Departemens of Pneumonology and Nuclear Medicine,
University of Crete Medical School, heraklion, Greece, Repiration; Jan/Feb
2002;69; Proquest
Ljiljana Vasic, 2007, A Role of Cyfra 21-1 Among Tumor Markers for Non-SmallCell Lung Cancer Acta Fac Med Naiss 2007; 24 (2): 65-69
Michael. E. Bromberg et al, 1999, Cancer and Blood Coaguloation: Molecular

Aspect, The Cancer Journal From Scientific American.
M. Roselli et al, 2014, Clinical models and biochemical predictors of VTE in lung
cancer, Department of Systems Medicine, Medical Oncology, Tor Vergata
Clinical Center, University of Rome “Tor Vergata”, Viale Oxford 81, 00133








Universitas Sumatera Utara

Paolo Prandoni et al, 2005, Cancer and venous thromboembolism, Department of
Medical and Surgical Sciences, Second Chair of Internal Medicine,
University of Padua, Padua, ItalyLancet Oncol 2005; 6: 401–10
Perhimpunan Dokter Paru Indonesia (PDPI), 2011, Kanker paru, Pedoman Diagnosis
dan penatalaksanaan di Indonesia, Perhimpunan Dokter Paru Indonesia,
Jakarta, 2011.
Peter Oppelt et al, 2015, Approach to chemotherapy-associated thrombosis, Case
Western Reserve University, Cleveland, OH 44106, USA, Vascular
Medicine 2015, Vol. 20(2) 153–161
Petra Stieber et al, 2006, National Academy of Clinical Biochemistry Guidelines for
the Use of Tumor Markers in Lung Cancer NACB: Practice Guidelines And
Recommendations For Use Of Tumor Markers In The Clinic Lung Cancer
(Section 3P, NACB.2006
P.P. Mumbarkar et al, 2006, Significance of Tumor Markers In Lung Cancer
Department of Biochemistry, Tata Memorial Hospital, Parel, Mumbai
Indian Journal of Clinical Biochemistry, 2006, 21 (1) 173-176

R Molina et al, 2003, Tumor Markers (CEA, CA 125, CYFRA 21-1,SCC and NSE)
in patients with Non-Small Cell Lung Cancer as an Aid in Histological
Diagnostic and Prognosis, Comparison with the Main Clinical and
Pathological Prognostic Factors, Laboratory of Clinical Biochemistry,Unit
for Cancer Research, Hospital Clinic and Unit of Epidemiology and Cancer

Universitas Sumatera Utara

Registry,Hospital I Duran I Reynals, Barcelona,

Tumor Biology

Salah Abbasi and Ahmed Badheed, Prognostic Factors in advanced Non-Small-Cell
Lung Cancer patients: Patient Characteristic and Type of Chemoterapy,
Clinical Oncology Department,King Hussien Center, Al-jubeiha, Amman
Shaker A. Mousaet al, 2004, Angiogenesis Inhibitors: Current & Future Directions,
Albany College of Pharmacy & Pharmaceutical Research Institute (PRI) at

Albany, Albany, NY and 1Cornell University, Ithaca, NY, USA Current
Pharmaceutical Depn, 2004, 10, 1-9
Slavica Kvolik, 2010, An overview of coagulation disorders in cancer patients,
Department of Anesthesiology and ICU, University Hospital Osijek, J.
Huttlera Osijek, Croatia, Surgical Oncology.
U.S. Cancer Statistics-working Group, 2012, United State Cancer Statistics 19992012, incidence and mortality web-based Report, Atalanta, U.S. Deparment
of Health and Human Services, Center of diseases Control and Prevention,
and National Cancer Institute, 2015. Available at: www.cdc.gov/uscs. .
Yuan liu et al, 2011, Tissue Factor-activated Coagulation Cascade in the tumor
Microenvironment in Critical for tumor Progression and an effective Target
for Therapy, Therapeutic, Targets and Chemical Biology, North Carolina,

Universitas Sumatera Utara